Food labeling: health claims; plant sterol/stanol esters and coronary heart disease. Food and Drug Administration, HHS. Interim final rule.
The Food and Drug Administration (FDA) is authorizing the use, on food labels and in food labeling, of health claims on the association between plant sterol/stanol esters and reduced risk of coronary heart disease (CHD).  FDA is taking this action in response to a petition filed by Lipton (plant sterol esters petitioner) and a petition filed by McNeil Consumer Healthcare (plant stanol esters petitioner).  Based on the totality of publicly available evidence, the agency has concluded that plant sterol/stanol esters may reduce the risk of CHD.
D003327:Coronary Disease / Q000188:drug therapy*; D005515:Food Labeling / Q000331:legislation & jurisprudence; D006801:Humans; D006937:Hypercholesterolemia / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D010840:Phytosterols / Q000627:therapeutic use*; D012307:Risk Factors; D014481:United States; D014486:United States Food and Drug Administration
D000960:Hypolipidemic Agents; D010840:Phytosterols